Premium
Diffuse large B‐cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome
Author(s) -
Chigrinova Ekaterina,
Mian Michael,
Scandurra Marta,
Greiner Timothy C.,
Chan Wing C.,
Vose Julie M.,
Inghirami Giorgio,
Chiappella Annalisa,
Baldini Luca,
Ponzoni Maurilio,
Ferreri Andrés J.M.,
Franceschetti Silvia,
Gaidano Gianluca,
Tucci Alessandra,
Facchetti Fabio,
Lazure Thierry,
Lambotte Olivier,
MontesMoreno Santiago,
Piris Miguel A.,
Nomdedeu Josep Fr.,
Uccella Silvia,
Rancoita Paola M.V.,
Kwee Ivo,
Zucca Emanuele,
Bertoni Francesco
Publication year - 2011
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.953
Subject(s) - diffuse large b cell lymphoma , lymphoma , bone marrow , medicine , infiltration (hvac) , chop , pathology , oncology , physics , thermodynamics
Abstract Bone marrow (BM) involvement in diffuse large B‐cell lymphoma (DLBCL) can be morphologically discordant from the primary tumor. Concordant BM infiltration has been shown associated with a poorer outcome in patients treated with CHOP. In order to evaluate tumor‐related factors leading to BM involvement in DLBCL, we performed an integrated analysis of i) genomic profiles obtained with a high‐density genome wide SNP‐based arrays ii) immunomorphological and iii) clinical data from 133 patients uniformly treated with R‐CHOP. BM infiltration was found in 27 of 133 (20%) cases; and it was concordant in 18/27 (67%) cases. Concordant infiltration, but not discordant, influenced negatively OS, PFS and DFS and was associated with higher serum LDH, lower CR and higher PD rates. No association with cell of origin was found between BM+ and BM‐ DLBCL. As compared with BM‐ cases, BM+ DLBCL showed absence of 7q gain. Copyright © 2010 John Wiley & Sons, Ltd.